Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002094 · ClinicalTrials.gov registry record · NA
Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E
A NA study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- NA
- Development phase
NCT00002094: Completed NA study, sponsored by Pharmacia and Upjohn.
NCT00002094 is a NA study that has completed, run by Pharmacia and Upjohn. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002094, a NA study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To determine the time course of development of resistance to atevirdine mesylate ( U-87201E ) in patients with HIV isolates showing in vitro resistance to zidovudine ( AZT ). To determine the genotype changes in HIV reverse transcriptase associated with in vitro AZT resistance to U-87201E. To determine the genotype and phenotype effects of treatment with a nondideoxynucleoside agent on the alterations of the HIV-1 population associated with in vitro AZT resistance. To determine whether serial passage of patient pre-drug HIV isolates in the presence of U-87201E will generate the resistant mutants that may subsequently emerge in the patients.
Interventions
- DRUG Atevirdine mesylate
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002094
The ClinicalTrials.gov registry entry for NCT00002094 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pharmacia and Upjohn, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atevirdine mesylate is the first listed.
NCT00002094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002094 about?
NCT00002094 is a clinical study titled "Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E". To determine the time course of development of resistance to atevirdine mesylate ( U-87201E ) in patients with HIV isolates showing in vitro resistance to zidovudine ( AZT ). To determine the genotype changes in HIV reverse transcriptase associated with in vitro AZT resistance to U-87201E. To determ...
What is the current status of trial NCT00002094?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002094?
The interventions under investigation include: Atevirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00002094?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.